推荐产品
种属反应性
human
包装
kit of 96 wells (12 strips x 8 wells)
技术
ELISA: suitable
输入
sample type urine
sample type plasma
sample type cell culture supernatant(s)
sample type serum
assay range
inter-assay cv: <10%
intra-assay cv: <12%
sensitivity: 30 pg/mL
检测方法
colorimetric
运输
wet ice
储存温度
−20°C
基因信息
human ... FGF19(9965)
一般描述
该ELISA抗体对可检测人成纤维细胞生长因子19。
应用
仅供研究使用。不可用于诊断操作。
请参考附带的一般ELISA试剂盒操作程序（夹心、竞争性 & 间接ELISA）
请参考附带的一般ELISA试剂盒操作程序（夹心、竞争性 & 间接ELISA）
生化/生理作用
成纤维细胞生长因子（FGF）19通过激活FGF受体4来控制靶器官中的胆汁酸、脂肪酸、葡萄糖和磷酸盐代谢。FGF19通过激活胰岛素非依赖性内分泌途径调节肝蛋白和糖原代谢。在糖尿病小鼠中，FGF19降低了血清葡萄糖和甘油三酸酯的水平。该基因的过度表达导致肝细胞癌（HCC）的发展。
其他说明
本产品提供样本检验报告。
请在批号对应的文本框中输入样品 一词。
请在批号对应的文本框中输入样品 一词。
试剂盒组分也可单独购买
产品编号
说明
化学品安全说明书
警示用语：
Warning
危险声明
预防措施声明
危险分类
Met. Corr. 1
储存分类代码
8A - Combustible corrosive hazardous materials
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
含少量动物源组分生物产品
常规特殊物品
Samer Al-Dury et al.
Journal of hepatology, 71(5), 986-991 (2019-06-30)
The nuclear farnesoid X receptor (FXR) agonist obeticholic acid (OCA) has been developed for the treatment of liver diseases. We aimed to determine whether OCA treatment increases the risk of gallstone formation. Twenty patients awaiting laparoscopic cholecystectomy were randomized to
José O Alemán et al.
Journal of translational medicine, 16(1), 244-244 (2018-09-05)
Microbiota and bile acids in the gastrointestinal tract profoundly alter systemic metabolic processes. In obese subjects, gradual weight loss ameliorates adipose tissue inflammation and related systemic changes. We assessed how rapid weight loss due to a very low calorie diet
Kai Wang et al.
Cell reports, 26(1), 222-235 (2019-01-04)
We demonstrated the metabolic benefits of Parabacteroides distasonis (PD) on decreasing weight gain, hyperglycemia, and hepatic steatosis in ob/ob and high-fat diet (HFD)-fed mice. Treatment with live P. distasonis (LPD) dramatically altered the bile acid profile with elevated lithocholic acid (LCA)
H Johansson et al.
Journal of internal medicine, 287(5), 534-545 (2020-01-25)
Fibroblast growth factor 19 (FGF19) is produced in the small intestine and is involved in suppression of hepatic bile acid (BA) synthesis. FGF19 is also expressed in the liver and serum levels are elevated in adults with cholestatic liver disease.
Samer Al-Dury et al.
Scientific reports, 8(1), 6658-6658 (2018-04-29)
Pruritus is a common complication of cholestatic liver diseases. Inhibition of the ileal bile acid transporter (IBAT/ASBT) may emerge as treatment option. Our aim was to assess tolerability and effect on pruritus of the selective IBAT inhibitor A4250 in patients
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门